Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. [electronic resource] by
- Wood, Robin
- Eron, Joseph
- Arasteh, Keikawus
- Teofilo, Eugenio
- Trepo, Christian
- Livrozet, Jean-Michel
- Yeo, Jane
- Millard, Judith
- Wire, Mary Beth
- Naderer, Odin J
Producer: 20050531
In:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 39
Availability: No items available.
|
|
10.
|
|
|
11.
|
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. [electronic resource] by
- Wood, Robin
- Arasteh, Keikawus
- Stellbrink, Hans-Jürgen
- Teofilo, Eugenio
- Raffi, François
- Pollard, Richard B
- Eron, Joseph
- Yeo, Jane
- Millard, Judith
- Wire, Mary Beth
- Naderer, Odin J
Producer: 20040220
In:
Antimicrobial agents and chemotherapy vol. 48
Availability: No items available.
|